FRAMINGHAM, MA, February 5, 2007-GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB), announced today that Geoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled to present on Monday, February 12, 2007 at 12:30 p.m. Eastern Time during the BIO CEO & Investor Conference 2007. The conference is being held at the Waldorf Astoria, New York, New York from February 12-14, 2007.
The presentation will be webcast live and can be accessed by logging onto www.gtc-bio.com. Replays can be accessed from this same website and will be available within 24 hours of the presentation.
GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. In August 2006, ATrynŽ, GTC's recombinant form of human antithrombin, was approved by the European Commission for use in patients with hereditary antithrombin deficiency undergoing surgical procedures. This was the first approval anywhere in the world of a therapeutic protein produced from a transgenic animal. ATrynŽ is in phase III studies to support a filing in the United States requesting approval in the hereditary deficiency indication. In addition, GTC established a strategic collaboration with LFB Biotechnologies of France to jointly develop recombinant forms of human plasma proteins and monoclonal antibodies. The first program of the collaboration will be to develop recombinant human factor VIIa as a potential treatment for hemophilia in patients with antibodies to other coagulation factors.
GTC has also recently been granted a patent in the United States through 2021 for the production of any therapeutic protein in the milk of any transgenic mammal. GTC's transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as those that are required in large volumes. Additional information is available on the GTC web site, http://www.gtc-bio.com.
CONTACT:
GTC Biotherapeutics, Inc.
Thomas E. Newberry
Vice President, Corporate Communications
(508) 370-5374 Feinstein Kean Healthcare
Francesca DeVellis (investors)
(617) 577-8110
Copyright 2007 GTC Biotherapeutics, All Rights Reserved